Helicobacter Pylori Testing Market
Report ID: SQMIG35D2552
Report ID: SQMIG35D2552
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35D2552 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
119
|Figures:
77
Global Helicobacter Pylori Testing Market size was valued at USD 486.2 Million in 2024 and is poised to grow from USD 516.83 Million in 2025 to USD 842.59 Million by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
The market for testing is mostly driven by the increasing recognition of Helicobacter pylori as a modifiable cause of gastritis, peptic ulcer disease and gastric cancer, which forces clinicians and health systems to detect and treat infection. The market covers laboratory and point-of-care diagnostics including urea breath tests, stool antigen assays, serology and PCR. Why it matters: Early diagnosis enables targeted eradication and reduces complications. Over the past 2 decades, culture and histology, which had been dependent on endoscopy, were replaced with noninvasive high-throughput and molecular assays; for example, in Europe, urea breath testing became more popular and in Asia, stool antigen testing gained popularity.
Increasing rates of failure to clarithromycin force clinicians to look for diagnostics that can identify resistance and confirm eradication. Antibiotic resistance has become the most important determinant of global market dynamics. As resistance increases, so too is the use of molecular testing and point-of-care PCR to guide therapy, allowing physicians to individualize regimens and avoid ineffective therapies; for example, in European and Asian clinics, stool PCR tests that identify 23S rRNA mutations can guide the decision between clarithromycin-containing triple therapy and bismuth quadruple therapy. This creates opportunity for diagnostic manufacturers to develop regulatory cleared resistance assays, expand laboratory services and partner with stewardship programs, creating opportunities, thereby driving revenue, improving patient outcomes.
How is AI improving diagnostic accuracy in the Helicobacter pylori testing market?
AI is sharpening diagnostic accuracy across Helicobacter pylori testing by supporting image based and laboratory workflows. Key testing approaches include urea breath tests stool antigen assays and endoscopic biopsy with histopathology. In practice deep learning models identify subtle mucosal patterns on endoscopic images and reduce variability in clinician readings. AI algorithms trained on whole slide pathology highlight organisms and guide pathologists toward challenging cases. Market momentum favors AI enabled reporting and automated platforms that speed interpretation and unify results across sites. A recent systematic review documents expanding clinical evidence for these AI diagnostic applications.
Biomerica March 2026, the company received its first commercial order for an H. pylori test which broadens distribution and sample volume. This expansion creates more annotated data and incentives for integrating AI into workflows which will improve model training and diagnostic efficiency across laboratories and clinics.
Market snapshot - (2026-2033)
Global Market Size
USD 486.2 Million
Largest Segment
Non-Invasive Tests
Fastest Growth
Non-Invasive Tests
Growth Rate
6.3% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global helicobacter pylori testing market is segmented by test type, technology, end user, application and region. Based on test type, the market is segmented into Non-Invasive Tests and Invasive Tests. Based on technology, the market is segmented into Immunoassays, Molecular Diagnostics, Microbiological Culture Methods, Histopathology-Based Methods and Breath Analysis Technologies. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Specialty Gastroenterology Clinics and Academic & Research Institutes. Based on application, the market is segmented into Initial Diagnosis, Post-Treatment Monitoring & Eradication Confirmation and Research Applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Non-Invasive Tests segment holds a dominant position as these methods reduce patient burden and widen testing access across care settings, allowing routine screening and follow up without invasive procedures. Their ease of sample collection and compatibility with primary care workflows makes them the preferred choice for clinicians and their low procedural risk makes them acceptable to patients. These factors along with simplified laboratory processing and guideline support for the initial diagnosis generate ongoing demand and institutional acceptance that supports market leadership.
However, the fastest growing area is Invasive Tests, as the need for definitive diagnosis and antibiotic susceptibility from biopsy driven testing continues to drive adoption in complex cases, while improvements in endoscopic biopsy workflows and molecular assays on tissue samples are creating new clinical value and market opportunity.
Immunoassays are currently dominating the market. Antigen and antibody based tests have been demonstrated to be reliable, scalable workflows that integrate well into routine laboratory operations and screening programs. It can be widely implemented in hospitals and diagnostic laboratories due to its wide platform compatibility and low complexity of operations. Reagent availability and regulatory clarity will increase adoption. The assays are amenable to rapid turnaround and can be integrated into automated analyzers, impacting purchasing decisions and sustaining demand across clinical and institutional testing pathways.
On the other hand , Molecular Diagnostics is the fastest growing technology with demand for accurate detection of pathogens and resistance markers driving the adoption , Progress in PCR platforms and sample to answer workflows enable targeted therapy decisions . Regulatory support and inclusion in antimicrobial stewardship programs will drive clinical adoption and important future growth and testing opportunities.
To get detailed segments analysis, Request a Free Sample Report
North America is projected to lead the global Helicobacter Pylori testing market over the forecast period, owing to its advanced clinical infrastructure, well-established diagnostic pathways and high adoption of molecular and non-invasive testing techniques. Early detection and linkage to care is facilitated by high clinician awareness and coordinated screening approaches in high risk settings . . “Strong reimbursement frameworks and a proactive role for diagnostic manufacturers are driving product availability and incremental innovation. The focus on research and clinical validation means moving new assays rapidly into practice. Strategic partnerships between laboratories, hospitals and industry ensure quality assurance and wide geographical coverage. The market is strengthening with a focus on antimicrobial stewardship and personalized treatment protocols through accurate testing. North America leads the way in clinical standards and commercial scale in Helicobacter Pylori diagnostics.
US Helicobacter Pylori Testing Market: Large Laboratory Networks, Early Adoption of Advanced Diagnostic Modalities, and Integrated Care Pathways with Test-Guided Therapy Alignment with clinical guidelines, proactive surveillance of antimicrobial resistance and strong private sector investment ensure access and product diversity. Academic center-industry partnerships are needed to facilitate rigorous validation of assays and education of clinicians to translate diagnostic innovation into practice for inpatient and outpatient settings.
Presence of centralized laboratories, evidence based diagnostic pathways promoting proper testing and follow up and coordinated national health initiatives are driving the growth of the Canada Helicobacter Pylori Testing Market. Assay evaluation, integration into workflows supported by academic networks, provincial programs. The focus is on quality assurance and interoperability of laboratory information systems, to enhance test reporting and to support clinical decision making. Industry involvement to increase the capacity of urban and regional diagnostic platforms.
In Europe, growth is driven by harmonizing clinical guidelines, an increased focus on diagnostic stewardship, and coordinated public and private efforts to accelerate the uptake of established and new testing approaches. Quality control and dissemination of validated assays are supported by strong laboratory networks and centralized reference facilities. Access and comparative evaluation of testing modalities are facilitated by cross-border research collaboration and pan-regional reimbursement discussions. The increasing awareness of the patterns of antimicrobial resistance and the role of targeted therapy encourages clinicians to use diagnostic tools more routinely. Europe constitutes a vibrant region for the scale-up of the Helicobacter Pylori testing across different health care systems . Regulatory pathways are amenable to innovative platforms and industry investment in market tailored solutions. Collaboration with payers and national authorities on diagnostic pathways and clinician education improves market uptake and consistency of care. All care settings enhanced via local manufacture and bespoke distribution.
Helicobacter Pylori Test Industry Germany has a robust clinical research infrastructure, sufficient lab capacity and pre-existing reimbursement mechanisms to support assay adoption. University centers and industry partnerships are supporting rigorous validation and uptake of molecular and noninvasive testing approaches. Reference laboratory networks and quality management promote consistent performance and clinician confidence. Market maturity supported by strategic initiatives targeting resistance trend tracking and integration of diagnostics into care pathways.
The UK Helicobacter Pylori Testing Market is growing at a fast pace due to national health programs, growing focus on antimicrobial stewardship and adoption of point of care and molecular diagnostics. Investment in clinician education and referral pathways leads to timely and appropriate diagnosis and treatment decisions. Interaction between central laboratories, community services and industry could support the scalable implementation of validated assays. Market is driven by changing commissioning approaches and a focus on diagnostic value across care settings.
Emergence of reinforced clinical guidelines, health campaigns and engagement with diagnostic innovation. New assay evaluation and education of clinicians are led by regional reference laboratories and academic centers. “Conversations about reimbursement and pilots are moving molecular and non-invasive testing into routine care.” Clinician adoption is growing with programs connecting testing to antimicrobial stewardship and treatment optimization and industry partnerships that improve distribution and training across care settings.
The Asia Pacific region is increasing its input into H. pylori testing through investment in modernization of laboratories, targeted public health campaigns and region-specific research to adapt diagnostic methods to address unique clinical needs. Molecular diagnostics and an increased emphasis on antimicrobial resistance surveillance are leading to improved detection accuracy and treatment strategies. Local manufacturers have joined hands with global developers to accelerate technology transfer and market penetration. Health system reforms are broadening their scope and are prioritizing diagnostic capacity and expanding access beyond the major urban centres. Training programs and validation studies focused on a region boost clinician confidence and distribution and service models designed to improve availability in a range of health care settings in the region. Regulatory harmonization and more efficient approval processes are accelerating market access for innovative assays. Pilot projects integrating diagnostics with primary care and community screening are establishing models for scale. Mobilizing resources, private sector engagement and cross-sectoral alliances also provide support for the implementation of sustainability.
Japan’s strong clinical research infrastructure, advanced laboratory capabilities and culture of diagnostic innovation are conducive to the adoption of molecular and noninvasive testing. Robust assay validation and clinical implementation are facilitated through collaboration of academic centers, hospitals and industry. Emphasis on antimicrobial resistance surveillance and coordinated care pathways promotes diagnostic driven therapeutic decisions. Local manufacturing allows the development of test platforms and service models that can be adapted to a national spectrum of clinical environments.
Helicobacter Pylori Testing Market Size, Share, Growth 2023-2031 South Korea is investing in diagnostic technology, lab infrastructure and cooperative networks connecting hospitals and community clinics. We use molecular methods and surveillance of antibiotic resistance to guide clinician decisions and personalized therapy. Validation studies and distribution of assays supported by public-private partnerships. Training activities and digital reporting systems in urban and regional health care are bettering the use of tests and their integration in care paths.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Adoption Of Noninvasive Tests
Expanded Government Screening Programs
Limited Access In Low Resource Settings
Reimbursement and Regulatory Challenges
Request Free Customization of this report to help us to meet your business objectives.
The global Helicobacter Pylori Testing Market is highly consolidated, with the top five healthcare diagnostic giants collectively commanding over 50% of the market share. Abbott Laboratories maintains the leading global position, closely rivaled by Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Laboratories, and Quest Diagnostics. Competition is intensely centered on a major clinical shift away from traditional, invasive endoscopy and rapid urease tissue biopsies toward highly accurate, non-invasive diagnostic platforms. Market leaders are heavily investing in expanding their molecular diagnostics and automated immunoassay portfolios, specifically optimizing high-throughput Urea Breath Tests (UBT) and non-invasive Stool/Fecal Antigen tests. Furthermore, specialized players like Meridian Bioscience and DiaSorin compete aggressively by rolling out rapid point-of-care (POCT) kits to capture decentralized outpatient clinics.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, a key driver is growing clinical recognition of Helicobacter pylori as a treatable cause of gastritis, peptic ulcer disease and gastric cancer, which is increasing demand for diagnostic testing. A major restraint is limited access in low resource settings where scarce laboratory infrastructure and trained personnel hinder consistent service delivery. North America remains the dominating region due to advanced clinical infrastructure and reimbursement support, and Non-Invasive Tests are the dominating segment because they lower patient burden and enable wider screening. A second driver is rising antibiotic resistance, which is accelerating adoption of molecular and resistance‑detecting assays to guide targeted therapy.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 486.2 Million |
| Market size value in 2033 | USD 842.59 Million |
| Growth Rate | 6.3% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Helicobacter Pylori Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Helicobacter Pylori Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Helicobacter Pylori Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Helicobacter Pylori Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Helicobacter Pylori Testing Market size was valued at USD 486.2 Million in 2024 and is poised to grow from USD 516.83 Million in 2025 to USD 842.59 Million by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).
I cannot verify two startups founded in 2019 or later that focus specifically on Helicobacter pylori testing. Do you want me to instead include verified companies that recently launched H pylori tests regardless of founding year, or include diagnostics startups founded since 2019 that offer H pylori testing as part of a broader panel? 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd.', 'Danaher Corporation', 'Bio-Rad Laboratories, Inc.', 'Thermo Fisher Scientific Inc.', 'DiaSorin S.p.A.', 'QuidelOrtho Corporation', 'Meridian Bioscience, Inc.', 'Sekisui Diagnostics, LLC', 'Coris BioConcept SA', 'Certest Biotec S.L.', 'Diagnostic BioSystems, Inc.', 'Trinity Biotech plc', 'Acon Laboratories, Inc.', 'Alfa Scientific Designs, Inc.', 'CerTest Diagnostics GmbH', 'Linear Chemicals S.L.U.', 'SD Biosensor, Inc.', 'Bioneer Corporation', 'Biomerica, Inc.'
Noninvasive Helicobacter pylori tests, such as stool antigen assays and breath tests, have become more widely accepted because they offer patient convenience and reduce barriers to sample collection. This acceptance motivates clinicians to recommend testing earlier and more frequently, supporting greater market uptake and demand for diverse testing platforms. Increased comfort among patients leads to higher screening participation, while ease of integration into primary care workflows encourages adoption by healthcare providers, collectively driving broader utilization and commercial expansion of testing solutions.
Noninvasive Testing Adoption: The market is shifting toward noninvasive Helicobacter pylori diagnostics such as breath and stool antigen assays that emphasize patient comfort and ease of sample collection. This trend encourages testing in primary care and outpatient settings, shortens diagnostic pathways and supports test and treat strategies without invasive endoscopy. Developers are prioritizing rapid turnaround, simplified workflows and user friendly kits to expand screening and post therapy confirmation, improving adherence and enabling broader and more sustainable implementation across clinical practices.
Why does North America Dominate the Global Helicobacter Pylori Testing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
